Table 5. Multivariate analysis of prognostic factors associated with survival and PFS.
| Characteristics | MST | HR (95% CI) | p | PFS | HR (95% CI) | p |
|---|---|---|---|---|---|---|
| Numbers of cycle | ||||||
| N ≥ 4 | 20.5 | 0.753 | 0.448 | 11.4 | 0.271 | < 0.001 |
| 0.362–1.566 | 0.141–0.521 | |||||
| N < 4 | 17.0 | Ref. | 6.5 | Ref. | ||
| Treatment Modality | ||||||
| Chemoradiotherapy | 21.5 | 0.267 | < 0.001 | 11.6 | 0.349 | < 0.001 |
| 0.128–0.555 | 0.176–0.615 | |||||
| Chemotherapy | 15.3 | Ref. | 7.0 | Ref. | ||
| LDH | ||||||
| Elevated (> 240 U/l) | 17.5 | 1.894 | 0.016 | 7.5 | 1.952 | 0.008 |
| 1.124–3.193 | 1.195–3.188 | |||||
| Normal (≤ 240 U/l) | 22.6 | Ref. | 13.5 | Ref. | ||
| NSE | ||||||
| Elevated (> 18 ng/ml) | 18.1 | 1.373 | 0.117 | 9.1 | 1.513 | 0.020 |
| 0.852–2.231 | 1.292–1.902 | |||||
| Normal (≤ 18 ng/ml) | 22.8 | Ref. | 14.5 | Ref. | ||
| NLR | ||||||
| Elevated (≥ 4) | 17.8 | 2.043 | 0.043 | 8.2 | 1.748 | 0.016 |
| 1.017–4.098 | 1.110–2.753 | |||||
| Normal (< 4) | 23.2 | Ref. | 13.8 | Ref. | ||
| Platinum Status | ||||||
| Sensitive | 21.1 | 0.561 | 0.036 | 13.2 | 0.333 | < 0.001 |
| 0.327–0.962 | 0.197–0.565 | |||||
| Refractory | 16.8 | Ref. | 8.4 | Ref. | ||
| Response | ||||||
| CR + PR | 21.8 | 0.592 | 0.076 | 13.0 | 0.384 | 0.021 |
| 0.333–1.054 | 0.187–0.808 | |||||
| SD + PD | 17.0 | Ref. | 7.8 | Ref. |
Abbreviations: PFS: progression-free time; MST: median survival time; HR: hazard ratio; CI: confidence interval; LDH: lactate dehydrogenase; NSE: neuro-specific enolase; NLR: neutrophil-to-lymphocyte ratio; CR: complete response; PR: partial response; SD: disease stable; PD: disease progression.